If you have been reading about HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-29. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Timothy Jostling & Donna Roberts (2001). "The Beef Hormone Dispute Between The United States and the EU". In Gerald C. Nelson (ed.). Genetically Modified Organisms in Agriculture: Economics and Politics. Academic Press. pp. 291–294. ISBN 0-12-515422-4. William A Kerr & Jill E Hobbs (February 2002). "The North American-European Union Dispute Over Beef Produced Using Growth Hormones: A Major Test for the New International Trade Regime". The World Economy. 25 (2): 283–296. doi:10.1111/1467-9701.00431. S2CID 154707486. SSRN 309524. Michael Balter (28 May 1999). "Scientific cross-claims fly in continuing beef war". Science. 284 (5419): 1453–1455. doi:10.1126/science.284.5419.1453. PMID 10383320. S2CID 5519384.
Ari Parata is a fictional character from the Australian television soap opera Home and Away, played by Rob Kipa-Williams. The actor had given up acting and was training for a new career as an insurance adviser when he was given the character brief for Ari. He was initially unsure about returning to acting, but he felt like the character was a good fit for him and he auditioned for the role. After winning the part, Kipa-Williams realised that he would have to relocate to Sydney for filming. He had doubts about the move, but later admitted that he was happy he went through with it, as Home and Away helped him regain his love of acting. Kipa-Williams signed a three-year contract and he began filming around May 2019. He made his first appearance during the serial's season finale on 27 November 2019. Ari was introduced along with his brother Tane Parata (Ethan Browne), their nephew Nikau Parata (Kawakawa Fox-Reo), and sister-in-law Gemma Parata (Bree Peters). They were the serial's first Māori and indigenous family to join the main cast of Home and Away. The actors wanted to include as much of the Māori culture in the show as possible and worked with the producers and scriptwriters to achieve a high level of authenticity. Ari is portrayed as being very protective of his family, but he dislikes confrontation and struggles to express his emotions. Kipa-Williams believed he was "a little bit lost", which he could relate to. It quickly emerges that Ari has spent time in prison and he is frequently frustrated about the limited opportunities available to him because of his record.
== Contrast with subduction zone island arcs == Hotspot volcanoes are considered to have a fundamentally different origin from island arc volcanoes. The latter form over subduction zones, at converging plate boundaries. When one oceanic plate meets another, the denser plate is forced downward into a deep ocean trench. This plate, as it is subducted, releases water into the base of the over-riding plate, and this water mixes with the rock, thus changing its composition causing some rock to melt and rise. It is this that fuels a chain of volcanoes, such as the Aleutian Islands, near Alaska.
== Toxicity rates == In earlier years it was thought that apamin was a rather nontoxic compound (LD50 = 15 mg/kg in mice) compared to the other compounds in bee venom. The current lethal dose values of apamin measured in mice are given below. There are no data known specific for humans. Intraperitoneal (mouse) LD50: 3.8 mg/kg Subcutaneous (mouse) LD50: 2.9 mg/kg Intravenous (mouse) LD50: 4 mg/kg Intracerebral (mouse) LD50: 1800 ng/kg Parenteral (mouse) LD50: 600 mg/kg
Sources: en.wikipedia.org
== Production == Lucia Aniello, Paul W. Downs, and Jen Statsky developed the idea for Hacks on a road trip in 2015. The three worked together previously on Broad City, and Aniello and Downs are romantic partners. HBO Max ordered the pilot for Hacks, a single-camera comedy series, from co-creators Aniello, Downs, and Statsky in January 2020, and then picked it up for a 10-episode order in May 2020. The series is co-executive produced with Michael Schur (Fremulon), and David Miner and Morgan Sackett (3 Arts Entertainment). Hacks is produced by Universal Television. On February 8, 2021, Jean Smart and Hannah Einbinder were announced as the two lead cast members and Carl Clemons-Hopkins was announced as a main cast member. Additional recurring cast members were also announced: Kaitlin Olson, Christopher McDonald, co-creator Paul W. Downs, Mark Indelicato, Poppy Liu, Johnny Sibilly, Meg Stalter, and Rose Abdoo. The series premiered on May 13, 2021, with the release of episodes one and two.
Yamni Nigam FRES is a British entomologist. She is a professor at Swansea University. Her scientific research focuses on the immune system of insects and invertebrates. She has a particular interest in wound healing and maggot (larval) therapy. Nigam additionally lectures on anatomy, physiology and pathophysiology within the School of Health & Social Care in the Faculty of Medicine, Health & Life - science at Swansea University.
== Treatment == Available treatment falls into two modalities: treating infections and boosting the immune system. Prevention of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is useful in those who are immunocompromised. In the early 1950s, immunoglobulin (Ig) was used by doctors to treat patients with primary immunodeficiency through intramuscular injection. Ig replacement therapy infusions can be either subcutaneous or intravenously administered, resulting in higher Ig levels for about three to four weeks, although this varies with each patient.
Sources: en.wikipedia.org
Sucrose esters or sucrose fatty acid esters are a group of non-naturally occurring surfactants chemically synthesized from the esterification of sucrose and fatty acids (or glycerides). This group of substances is remarkable for the wide range of hydrophilic-lipophilic balance (HLB) that it covers. The polar sucrose moiety serves as a hydrophilic end of the molecule, while the long fatty acid chain serves as a lipophilic end of the molecule. Due to this amphipathic property, sucrose esters act as emulsifiers; i.e., they have the ability to bind both water and oil simultaneously. Depending on the HLB value, some can be used as water-in-oil emulsifiers, and some as oil-in-water emulsifiers. Sucrose esters are used in cosmetics, food preservatives, food additives, and other products. A class of sucrose esters with highly substituted hydroxyl groups, olestra, is also used as a fat replacer in food.
=== Honours and awards === 1990, Meldola Medal awarded from the Royal Society of Chemistry (RSC) 1993, Zeneca Award for Organic Chemistry from AstraZeneca 1997, Hickinbottom Fellowship from the Royal Society of Chemistry 1999, Novartis Chemistry Lectureship 2003, Inaugural winner of the Royal Society's Rosalind Franklin Award. She used the award to fund a series of UK lectureships for internationally renowned female chemists. 2013, Gibson was appointed an Officer of the Most Excellent Order of the British Empire (OBE) for services to Chemistry and Science Education in the 2013 New Year Honours
==== Evolution of animal synthesis ==== Ascorbic acid is a common enzymatic cofactor in mammals used in the synthesis of collagen, as well as a powerful reducing agent capable of rapidly scavenging a number of reactive oxygen species (ROS). Given that ascorbate has these important functions, it is surprising that the ability to synthesize this molecule has not always been conserved. In fact, anthropoid primates, Cavia porcellus (guinea pigs), teleost fishes, most bats, and some passerine birds have all independently lost the ability to internally synthesize vitamin C in either the kidney or the liver. In all of the cases where genomic analysis was done on an ascorbic acid auxotroph, the origin of the change was found to be a result of loss-of-function mutations in the gene that encodes L-gulono-γ-lactone oxidase, the enzyme that catalyzes the last step of the ascorbic acid pathway outlined above. One explanation for the repeated loss of the ability to synthesize vitamin C is that it was the result of genetic drift; assuming that the diet was rich in vitamin C, natural selection would not act to preserve it.
Naltrexone itself produces little or no psychoactive effect in normal research volunteers even at high doses, which is remarkable given that the endogenous opioid system is important in normal hedonic functioning. Because endogenous opioids are involved in the brain reward system, it would be reasonable to hypothesize that naltrexone might produce anhedonic or dysphoric effects. Although some evidence from small, early trials suggested that patients with a history of opiate dependence might be susceptible to dysphoric effects in response to naltrexone (Crowley et al. 1985; Hollister et al. 1981), reports of such effects have been inconsistent. Most large clinical studies of recovering opioid-dependent individuals have not found naltrexone to have an adverse effect on mood (Greenstein et al. 1984; Malcolm et al. 1987; Miotto et al. 2002; Shufman et al. 1994). Some studies have actually found improvements in mood during the course of treatment with naltrexone (Miotto et al. 1997; Rawlins and Randall 1976). Based on available evidence, naltrexone seems to have minimal untoward effects in the aforementioned areas, at least with long-term therapy. It has been suggested that differences in findings between acute and longer-term studies of naltrexone treatment might be related to altered function in the opioid system with chronic administration of naltrexone. For example, marked upregulation of opioid receptors and hyper-sensitivity to opioids have been observed with naltrexone in preclinical studies.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.